35661-60-0 | Fmoc-leu-oh

Packsize	Purity	Availability	Price	Discounted Price
5g	98%	in stock	$6.00	$4.00
10g	98%	in stock	$8.00	$5.00
25g	98%	in stock	$13.00	$9.00
100g	98%	in stock	$42.00	$29.00
500g	98%	in stock	$172.00	$120.00
1kg	98%	in stock	$286.00	$200.00

Description

• Catalog Number: AI48784
• Chemical Name: Fmoc-leu-oh
• CAS Number: 35661-60-0
• Molecular Formula: C21H23NO4
• Molecular Weight: 353.4116
• MDL Number: MFCD10567377
• SMILES: CC(C[C@@H](C(=O)O)NC(=O)OCC1c2ccccc2-c2c1cccc2)C

Computed Properties

• Complexity: 484
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 4.4

Upstream Synthesis Route

Fmoc-L-Leucine is a key building block used in chemical synthesis, specifically in the field of peptide synthesis. Peptides are essential molecules in life sciences, serving as indispensable tools for drug discovery, biochemical research, and pharmaceutical development. By incorporating Fmoc-L-Leucine into peptide chains, chemists can strategically modify and design peptides with desired properties and functionalities. This amino acid derivative enables precise control over peptide structures and sequences, allowing for the creation of customized peptides tailored to specific research or therapeutic applications. In chemical synthesis, Fmoc-L-Leucine plays a crucial role in the development of novel peptides, providing researchers with a versatile tool to advance scientific knowledge and innovation in various industries.

Literature

• Study on cow ghee versus soybean oil on 7,12-dimethylbenz(a)-anthracene induced mammary carcinogenesis & expression of cyclooxygenase-2 & peroxisome proliferators activated receptor-γ in rats.

  The Indian journal of medical research 20110501

• Comparative dynamics of leucine methyl groups in FMOC-leucine and in a protein hydrophobic core probed by solid-state deuteron nuclear magnetic resonance over 7-324 K temperature range.

  The journal of physical chemistry. B 20101209

• The 20S proteasome splicing activity discovered by SpliceMet.

  PLoS computational biology 20100601

• Hydrogelation and self-assembly of Fmoc-tripeptides: unexpected influence of sequence on self-assembled fibril structure, and hydrogel modulus and anisotropy.

  Langmuir : the ACS journal of surfaces and colloids 20100406

• Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080801

• The PPARgamma agonist FMOC-L-leucine protects both mature and immature brain.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• 'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic Studies.

  PPAR research 20070101

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Characterization of compound mechanisms and secondary activities by BioMAP analysis.

  Journal of pharmacological and toxicological methods 20060101

• Self-assembly of small molecules affords multifunctional supramolecular hydrogels for topically treating simulated uranium wounds.

  Chemical communications (Cambridge, England) 20050921

• Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.

  Cancer research 20040201

• PPAR-gamma: a thrifty transcription factor.

  Nuclear receptor signaling 20030101

• Effect of NPC-15199 on Ca2+ levels in renal tubular cells.

  The Chinese journal of physiology 20020930

• PPARgamma, an X-ceptor for Xs.

  Annals of the New York Academy of Sciences 20020601